40 mg Pantoprazole and 40 mg Esomeprazole Are Equivalent in the Healing of Esophageal Lesions and Relief from Gastroesophageal Reflux Disease???related Symptoms

Gillessen, Anton; Beil, Winfried; Modlin, Irvin M.; Gatz, Gudrun; Hole, Ursula

doi:10.1097/00004836-200404000-00007

Cited by 62 publications

(58 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both drugs were safe well-tolerated. 18 Gillessen et al 19 and Scholten et al 20 have reported similar effectiveness for esomeprazole 40 mg and pantoprazole 40 mg, or even greater effectiveness for latter drug in terms of speed of symptom resolution. Crossover studies in healthy subjects and patients with symptoms of GERD have shown that esomeprazole is more effective than all other PPI for providing greater time with pH >4.…”

Section: Discussionmentioning

confidence: 94%

Comparative study of pantoprazole and esomeprazole for erosive gastroesophageal reflux disease: a prospective study

Givvimani

Jagadishbabu²,

Junied³

et al. 2014

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Comparative study of pantoprazole and esomeprazole for erosive gastroesophageal reflux disease: a prospective study

Givvimani

Jagadishbabu²,

Junied³

et al. 2014

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

“…However, to date there is no undisputed evidence of an appreciable difference in effectiveness between different PPIs at equivalent doses. In fact, clinical studies have not demonstrated any consistent difference between PPIs at similar doses with regard to clinical or endoscopic outcomes [2,15,16,17, 28]. …”

Section: Discussionmentioning

confidence: 99%

“…Esomeprazole and pantoprazole are both very effective and prove therapeutic equivalence in case of GERD [15,16,17], and are indicated for the treatment of enGERD, achieving adequate short-term symptom relief rates, particularly heartburn, and effective subsequent long-term symptomatic remission rates [18,19,20,21]. However, the prime concerns for many GERD patients, particularly for those with enGERD, are fast relief of pain and subsequently sustained symptom control, and therefore not only relief rates at a fixed date (e.g.…”

Section: Introductionmentioning

confidence: 99%

Novel Measurement of Rapid Treatment Success with ReQuest<sup>TM</sup>: First and Sustained Symptom Relief as Outcome Parameters in Patients with Endoscopy-Negative GERD Receiving 20 mg Pantoprazole or 20 mg Esomeprazole

et al. 2007

Self Cite

View full text Add to dashboard Cite

Background/Aims: A prime concern for gastroesophageal reflux disease (GERD) patients is fast symptom control. Sparse valid information is available on the rapidity of the effect of proton pump inhibitors in providing symptom relief. The new reflux questionnaire ReQuest^TM is validated for daily assessment of changes in GERD symptoms. Therefore, this study investigated the efficacy of 20 mg pantoprazole and 20 mg esomeprazole with regard to the time to symptom relief in patients with endoscopy-negative GERD (enGERD) using ReQuest^TM. Methods: 529 patients were treated with pantoprazole or esomeprazole over 4 weeks. ReQuest^TM symptom scores were assessed daily. The mean and median times to first and sustained symptom relief were determined. Results: Median time to first symptom relief was 2 days for both drugs (intention-to-treat population). The median time to sustained symptom relief was 3 days shorter with pantoprazole (10.0 vs. 13.0 days). The Hodges-Lehmann estimator for the difference in time to reach first and sustained symptom relief between both groups was 0.00 days. For both variables the one-sided 95% CI (Moses) was [0.00; ∞[, documenting no significant differences between the treatment groups. Conclusions: The rapidity of symptom control can be evaluated by clinically significant parameters using ReQuest^TM. Pantoprazole and esomeprazole are equally effective in the time to first and sustained symptom relief.

show abstract

“…Clinically, however, there appears to be no significant or consistent differences between the five available PPIs in terms of improving the symptoms or endoscopic healing of mucosal breaches when the PPIs are tested at similar doses [17]. …”

Section: The Evolution Of Gastrinmentioning

confidence: 99%

Edkins and a Century of Acid Suppression

et al. 2005

View full text Add to dashboard Cite

In 1905, John Edkins (1863–1940) undertook the studies of gastrin that have subsequently formed the basis for a century of investigation into the physiological basis of acid secretion and led to the elucidation of a variety of acid-suppressive pharmacological agents that have revolutionized the management of acid peptic disease. Although his name is known to few, his contributions to the physiology of gastric secretion and his study of spiral organisms in the stomach were prescient and to this day remain models of insightful and rigorous research. As a mentor, his educational impact was exemplified by the fact that he was the first to teach physiology to women in the United Kingdom. Gastrin has evolved from an initially unaccepted phenomenon, to be recognized as an important hormone and a fundamental component of regulatory biology as well as a clinically relevant biomarker of disease. Its critical role in the modulation of acid secretion has become a sine qua non and has been extended to include a broad regulatory proliferative role in the mucosa of the gastrointestinal tract. The pivotal role of gastrin in gastric physiology, biology and clinical medicine is now well accepted and reflects the fundamental contributions that Edkins made to the identification of the agent and the elucidation of its function. As a result of the delineation of the neural and hormonal regulatory mechanisms of acid secretion, the scientific basis of acid peptic disease has become apparent. The identification of histamine receptors and proton pumps has led to the discovery of novel pharmacotherapeutic agents capable of producing acid suppression of such efficacy that surgery has become virtually obsolete in the treatment of the disease process. A century after the initial observations by Edkins of gastrin, the identification of Helicobacter pylori and the ability to eradicate it, as well as the use of the proton pump inhibitor class of drugs, have revolutionized the management of gastroduodenal ulceration and gastroesophageal reflux disease. Both patients and physicians owe a great debt to Edkins, whose seminal observations regarding gastrin initiated an era of gastrointestinal scientific, clinical and pharmacological advance that has culminated in the ability to treat and cure acid peptic disease.

show abstract

40 mg Pantoprazole and 40 mg Esomeprazole Are Equivalent in the Healing of Esophageal Lesions and Relief from Gastroesophageal Reflux Disease???related Symptoms

Abstract: In patients with gastroesophageal reflux disease, 40 mg pantoprazole daily and 40 mg esomeprazole daily are equally effective for healing of esophageal lesions and relieving gastroesophageal reflux disease-related symptoms.

Cited by 62 publications

References 22 publications

Comparative study of pantoprazole and esomeprazole for erosive gastroesophageal reflux disease: a prospective study

Comparative study of pantoprazole and esomeprazole for erosive gastroesophageal reflux disease: a prospective study

Novel Measurement of Rapid Treatment Success with ReQuest<sup>TM</sup>: First and Sustained Symptom Relief as Outcome Parameters in Patients with Endoscopy-Negative GERD Receiving 20 mg Pantoprazole or 20 mg Esomeprazole

Edkins and a Century of Acid Suppression

Contact Info

Product

Resources

About